Orthocell Limited
(ASX:OCC) has announced it has been granted a patent in Canada relating to cells that make up healthy tendons.
The regenerative medicine company says the patent already follows granted patents in the USA, Singapore, China and New Zealand to provide a solid IP foundation for both cellular therapy for tendon regeneration and the collagen-based medical device Celgro.
The latest patent relates to the combination of cells and scaffolds to form a regenerative construct for tendons.
The patent will expire in April of 2028.
Orthocell reported a net loss of $3.74 million at 30 June 2015.
